|
|
 |
|
Viewing report
|
|
|
|
Algeria Pharmaceuticals and Healthcare Report Q1 2011
Business Monitor International, Nov 2010, Pages: 66
The Algeria Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Algeria's pharmaceuticals and healthcare industry.
In Q111, Algeria moved down one place in BMI’s Business Environment Ratings (BERs) to occupy eighth position of the 19 regional markets surveyed in the Middle East and Africa region. This adjustment now sees Algeria placed below Lebanon and above Egypt. Algeria’s pharmaceutical rating is 47.7 out of 100, which is above the average of 45.8 for the region. When taken in a global context, Algeria has also fallen one place to now occupy 48th position in BMI’s 83 market-strong pharmaceutical universe. The main draws of Algeria’s pharmaceutical market are its considerable size (with a population of over 35mn) and the substantial potential for healthcare investment, given the fact that the country is a major hydrocarbons exporter. However, the government remains accused of giving preferential treatment to generics products and the domestic industry, while the country’s wider intellectual property rights (IPRs) environment is also a cause for concern to multinationals operating there.
The incidence of diabetes (especially type II) is on the rise in Algeria as both affluence and urbanisation increase. Official figures estimate that around 8% of Algerians suffer from the condition. In addition, around 40,000 new cases of cancer are registered each year, although the country only has four specialist oncology centres. In response to mounting criticism about the lack of adequate treatment facilities, plans have been announced to increase the number of cancer treatment centres in Algeria from four to 17, as well as to build a National Cancer Care Institute in Oran. The Minister of Health, Djamel Ould Abbas, has also pledged to purchase more equipment.
In October 2010, the Algerian government signed a letter of intent with a number of US firms aimed at bringing much needed investment to the country’s pharmaceutical and healthcare sector in areas such as technology transfer, research and development (R&D) and direct investments. Investments are also expected to be made in a number of specialised healthcare services such as oncology centres. Domestic pharmaceutical group Saidal announced that it is to start work on a modernisation program worth EUR1.4mn (US$1.9mn) aimed at increasing production capacity at eight of its manufacturing facilities based in Algiers, Cherchell, and Medea. The improvements will increase Saidal’s drug production capabilities from 135mn to 298mn sales units, as well as raise the firm’s standards of quality to that of European levels. The improvements are being financed by a National Investment Fund loan, which allocated EUR180mn (US$251mn) to the Saidal Group’s five-year development plan in 2009. Elsewhere, Pfizer-Saidal Manufacturing (PSM), a collaboration between US pharmaceutical major Pfizer’s local subsidiary, Pfizer Pharm Algerie and domestic pharmaceutical firm Saidal, announced that it is to begin the production of an unspecified major anti-inflammatory treatment by the end of 2010. The anti-inflammatory medication is currently one of about 20 products imported by PSM, which also manufactures about 18 products at its Algiers plant.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
